Review
Pharmacology & Pharmacy
Ivan Guryanov, Tatiana Tennikova, Arto Urtti
Summary: VEGFs play crucial roles in angiogenesis, but dysregulation can lead to pathological angiogenesis in various diseases. Monoclonal antibodies and decoy receptors are commonly used to neutralize VEGFA in anti-angiogenic therapies. Short peptides are promising alternatives to full-length VEGFA inhibitors, overcoming some limitations of existing therapies.
Review
Biochemistry & Molecular Biology
Syeda Mahak Zahra Bokhari, Peter Hamar
Summary: Vascular endothelial growth factors (VEGFs) play a crucial role in regulating blood vessel formation in both normal and cancer development. VEGF-A is the most well-studied angiogenic factor secreted by tumor cells, making it a rational target for anticancer therapy. However, inhibiting VEGF-A can lead to the upregulation of VEGF-D, which has been shown to have comparable blood angiogenic potential and may facilitate tumor growth. This review focuses on summarizing the angiogenic role of VEGF-D in blood vessel formation and its potential as a therapeutic target for antiangiogenic therapy in cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Chemistry, Medicinal
Die Jiang, Ting Xu, Lei Zhong, Qi Liang, Yonghe Hu, Wenjing Xiao, Jianyou Shi
Summary: Angiogenesis is a vital biological process for body growth and development, wound healing, and tissue formation. Dysregulation of VEGFR signaling can lead to diseases, making it a crucial research area for disease treatment. Currently, anti-VEGF drugs used in ophthalmology have limitations, and there is a need to develop small molecule inhibitors of VEGFR for the targeted treatment of ocular neovascularization diseases.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Developmental Biology
Baptiste Coxam, Russell T. Collins, Melina Hussmann, Yvonne Huisman, Katja Meier, Simone Jung, Eireen Bartels-Klein, Anna Szymborska, Lise Finotto, Christian S. M. Helker, Didier Y. R. Stainier, Stefan Schulte-Merker, Holger Gerhardt
Summary: This study identifies blood flow and the extracellular protein Svep1 as co-modulators of blood vessel anastomosis in zebrafish embryos. Loss of Svep1 and reduction of blood flow both contribute to defective vessel anastomosis. The study also suggests that the Vegfa/Vegfr signaling pathway plays a role in the formation and lumenisation of blood vessels.
Review
Biochemistry & Molecular Biology
Peace Mabeta, Vanessa Steenkamp
Summary: The VEGF/VEGFR axis plays a crucial role in angiogenesis and tumor vascularization. Current therapies targeting VEGF and its receptors have shown limited effectiveness and undesirable off-target effects. Recent studies have identified VEGF splice variants that modulate angiogenesis, and their expression is regulated by cues within the tumor microenvironment. These variants challenge the established norm of VEGF signaling and their aberrant expression has been observed in several cancers, highlighting the need for further research on their role in cancer and their impact on antiangiogenic therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Catarina Nascimento, Andreia Gameiro, Joao Ferreira, Jorge Correia, Fernando Ferreira
Summary: Feline mammary carcinoma is the third most common neoplasia in cats, with highly malignant behavior. The study suggests that VEGF-A and its serum receptors assessment may have potential in the diagnosis and treatment of feline mammary carcinoma.
Article
Biochemistry & Molecular Biology
Zhibao Wang, Bo Cao, Peng Ji, Fan Yao
Summary: Propofol inhibits tubular structure formation and various biological functions of tumor-associated endothelial cells, including migration, adhesion, proliferation, and survival, by suppressing the expression and secretion of multiple pro-angiogenic factors and specific signaling pathways. These findings provide preclinical evidence for the anti-cancer properties of propofol and its potential mechanisms in inhibiting tumor growth and metastasis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Review
Cardiac & Cardiovascular Systems
Bronte Miller, Mary Kathryn Sewell-Loftin
Summary: Endothelial cells in the vascular system respond to mechanical forces, playing a critical role in maintaining blood vessel structure and function. Understanding the mechanisms of biomechanical regulation in vascular growth can lead to new therapeutic strategies for different diseases.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cell Biology
Fan Wang, CaiYan Li, Fei Han, LvAn Chen, Ling Zhu
Summary: The BMAL1 gene plays a crucial role in glioma tolerance for anti-angiogenesis therapy, as its expression is correlated with ANG2 and VEGF levels, microvascular density, and peritumoral edema. In vitro experiments show that silencing BMAL1 decreases VEGF expression, while overexpression promotes ANG2 and VEGF expression.
Article
Multidisciplinary Sciences
Ying Wang, Ramcharan Singh Angom, Tanmay A. Kulkarni, Luke H. Hoeppner, Krishnendu Pal, Enfeng Wang, Alexander Tam, Rachael A. Valiunas, Shamit K. Dutta, Baoan Ji, Natalia Jarzebska, Yingjie Chen, Roman N. Rodionov, Debabrata Mukhopadhyay
Summary: The study revealed that acute and chronic exposures to VEGF induce divergent signaling pathways. DDAH1 plays essential roles in both acute and chronic vascular permeability. The findings suggest that DDAH1 could be a potential therapeutic target for vascular hyperpermeability-mediated pathogenesis.
Review
Biochemistry & Molecular Biology
Genevieve A. Secker, Natasha L. Harvey
Summary: The importance of lymphatic vessels in human diseases, the initiation of lymphatic vascular development during embryogenesis, and the role of VEGF/VEGFR signaling in driving the construction of lymphatic vessels were discussed in this review.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Samaneh Ghasemali, Safar Farajnia, Abolfazl Barzegar, Mohammad Rahmati-Yamchi, Roghayyeh Baghban, Leila Rahbarnia, Hamid R. Y. Nodeh
Summary: This review explores the latest developments in anti-angiogenic agents, emphasizing their role in cancer treatment. Research shows that anti-angiogenesis agents, particularly in combination therapy, are effective in treating various cancers.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Lorenzo Fornaro, Gianna Musettini, Paola Orlandi, Irene Pecora, Caterina Vivaldi, Marta Banchi, Francesca Salani, Elisabetta Fini, Valentina Massa, Silvia Catanese, Federico Cucchiara, Monica Lencioni, Gianluca Masi, Enrico Vasile, Guido Bocci
Summary: Ramucirumab plus paclitaxel is considered standard treatment for second-line gastric carcinoma (GC) patients. This study evaluated plasma VEGF-A, VEGF-D, and sVEGFR-2 as potential markers of resistance or response to this treatment. Results showed significant increases in VEGF-A and VEGF-D levels during treatment, and early increase in sVEGFR-2 levels was associated with longer progression-free survival and overall survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Ophthalmology
Claudia Lange, Reimo Tetzner, Tobias Strunz, Kay D. Rittenhouse
Summary: Anti-VEGF therapies can suppress the production of VEGF as well as ANG2 protein and ANGPT2 mRNA, providing beneficial effects for the treatment of retinal diseases. Aflibercept demonstrates the greatest inhibitory effect on ANG2 levels, which correlates with strong and durable suppression of intraocular VEGF levels.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yongjie Li, Qian Gao, Xin Shu, Lamei Xiao, Yan Yang, Ningbo Pang, Yulin Luo, Jing He, Liping Zhang, Jianbo Wu
Summary: The study demonstrated that inhibition of alpha V beta 3 integrin improves blood flow perfusion and angiogenesis in a mouse hindlimb ischemia model, possibly through modulation of macrophage infiltration and polarization. This suggests that alpha V beta 3 integrin inhibition may be a promising therapeutic strategy for peripheral artery disease.
FRONTIERS IN PHARMACOLOGY
(2021)